Docetaxel (DCX) is a second generation
taxane. It is approved by the U.S. Food and Drug Administration for the treatment of various types of
cancer, including breast, non-small cell lung, and head and
neck cancers. However, side effects, including those related to
Tween 80, an
excipient in current DCX formulations, can be severe. In the present study, we developed a novel solid
lipid nanoparticle (SLN) composition of DCX.
Trimyristin was selected from a list of high melting point
triglycerides as the core
lipid component of the SLNs, based on the rate at which the DCX was released from the SLNs and the stability of the SLNs. The
trimyristin-based, PEGylated DCX-incorporated SLNs (DCX-SLNs) showed significantly higher cytotoxicity against various human and murine
cancer cells in culture, as compared to DCX solubilized in a
Tween 80/
ethanol solution. Moreover, in a mouse model with pre-established
tumors, the new DCX-SLNs were significantly more effective than DCX solubilized in a
Tween 80/
ethanol solution in inhibiting
tumor growth without toxicity, likely because the DCX-SLNs increased the concentration of DCX in
tumor tissues, but decreased the levels of DCX in major organs such as liver, spleen, heart, lung, and kidney. DCX-incorporated SLNs prepared with one or more high-melting point
triglycerides may represent an improved DCX formulation.